| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 19 May 2025 | 12 May 2025 |
| Amerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve PFA PFA (As Per BSE Announcement dated on 19.05.2025) | ||
| Board Meeting | 3 Feb 2025 | 22 Jan 2025 |
| Amerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve Pursuantto Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Monday 3rd February 2025 inter alia to consider following business. - 1.) To approve and take on record the Un-Audited Financial Results of the Company for the quarter ended on 31st December 2024. 2.) To approve and consider the appointment of Mr. Kelash Bunkar as Director of the Company. 3.) To consider the resignation of Mr. Niraj Vaghela from directorship of the Company. 4.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You. Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Monday 3rd February 2025 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and nine months ended on 31st December 2024. 2.) The board has considered and accepted the resignation of Independent Director Mr Niraj Vaghela w e.f 03.02.2025. 3.) Mr. Kelash Bunkar is appointed as non-executive independent director of the company w e f. 03.02.2025 subject to approval of members in AGM. The board meeting commenced at 05:40 PM and concluded at 06:00 PM Please take the above intimation in your records. (As Per BSE Announcement Dated on: 03/02/2025) | ||
| Board Meeting | 22 Oct 2024 | 15 Oct 2024 |
| Amerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/10/2024 inter alia to consider and approve PFA Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Tuesday 22th October 2024 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th September, 2024. The board meeting commented at 01.30 PM and concluded at 02.05 PM Read less.. (As Per BSE Announcement Dated on 22.10.2024) | ||
| Board Meeting | 6 Aug 2024 | 30 Jul 2024 |
| Amerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday 6th August 2024 inter alia to consider following business. Please take the above intimation in your records. Thanking You. PFA (As per BSE Announcement Dated on 06/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.